Method for manufacturing protein drug
US-9359397-B2 · Jun 7, 2016 · US
Method for treating solution contaminated with porcine circoviruses
US2019167823A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019167823-A1 |
| Application number | US-201716323996-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 8, 2017 |
| Priority date | Aug 9, 2016 |
| Publication date | Jun 6, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for treating a solution contaminated with porcine circovirus, comprising the steps of: adjusting a pH of a solution contaminated with porcine circovirus to range from 3.0 to 7.0; and treating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more.
First claim
Opening claim text (preview).
1 . A method for treating a solution contaminated with porcine circovirus, comprising: adjusting a pH of a solution contaminated with porcine circovirus to range from 3.0 to 7.0; and treating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more. 2 . The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the pH-adjusted solution contains not more than 0.50 M glycine. 3 . The method for treating a solution contaminated with porcine circovirus according to claim 2 , wherein the solution contains 0.010 to 0.40 M glycine. 4 . The method for treating a solution contaminated with porcine circovirus according to claim 2 , wherein the solution contains 0.20 to 0.35 M glycine. 5 . The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the solution contaminated with porcine circovirus contains not more than 5.0 w/v % of a protein. 6 . The method for treating a solution contaminated with porcine circovirus according to claim 5 , wherein when the protein concentration in the solution contaminated with porcine circovirus is less than 0.10 w/v %, the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.0 to 6.0. 7 . The method for treating a solution contaminated with porcine circovirus according to claim 5 , wherein when the protein concentration of the solution contaminated with porcine circovirus ranges from 0.10 to 1.5 w/v %, the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.8 to 7.0. 8 . The method for treating a solution contaminated with porcine circovirus according to claim 5 , wherein the protein is IgG. 9 . The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the pH-adjusted solution is treated at 50 to 100 L/m 2 . 10 . The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the LRV for porcine circovirus is 2 or more. 11 . A method for treating a solution, comprising: adjusting a pH of a solution to be treated to range from 3.0 to 7.0; and treating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more. 12 . The method for treating a solution contaminated with porcine circovirus according to claim 2 , wherein the solution contaminated with porcine circovirus contains not more than 5.0 w/v % of a protein. 13 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein the solution contains 0.010 to 0.40 M glycine. 14 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein the solution contains 0.20 to 0.35 M glycine. 15 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein when the protein concentration in the solution contaminated with porcine circovirus is less than 0.10 w/v %, the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.0 to 6.0. 16 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein when the protein concentration of the solution contaminated with porcine circovirus ranges from 0.10 to 1.5 w/v %, the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.8 to 7.0. 17 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein the protein is IgG. 18 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein the pH-adjusted solution is treated at 50 to 100 L/m 2 . 19 . The method for treating a solution contaminated with porcine circovirus according to claim 12 , wherein the LRV for porcine circovirus is 2 or more.
Assignees
Inventors
Classifications
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title
DNA viruses · CPC title
- A61L2/022Primary
Filtration · CPC title
- A61L2/0017Primary
Human Necessities · mapped topic
- C07K1/34Primary
by filtration, ultrafiltration or reverse osmosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019167823A1 cover?
- The present invention provides a method for treating a solution contaminated with porcine circovirus, comprising the steps of: adjusting a pH of a solution contaminated with porcine circovirus to range from 3.0 to 7.0; and treating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more.
- Who is the assignee on this patent?
- Asahi Kasei Medical Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61L2/022. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jun 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).